BBC World News reported about our online medicine service on their program
Patients taking new weight loss/diabetes drugs such as semaglutide (Wegovy), and their doctors, need to be aware of the significant risk they pose for sedation or anesthesia, writes anesthesiologist Paul Kempen, M.D., in the summer issue of the Journal of American Physicians and Surgeons
If your provider is not familiar with the indirect connections between GLP-1 therapy and urinary health, sharing the research discussed in this article can facilitate a more informed conversation
In animal models of heart failure induced by high-frequency pacing, ischaemia, and obesity, GLP-1RAs inhibit left ventricular remodelling and improve left ventricular contractility and diastolic function through anti-inflammatory effects, cardiomyocyte apoptosis inhibition, and glucose metabolism enhancement in cardiomyocytes [38,39,40]
In patients with type 2 diabetes, the ability of their bodies to respond to GLP-1 and stimulate insulin secretion is reduced, Quinones explains